Results 241 to 250 of about 49,575 (291)

Stereotactic body radiotherapy

BMJ, 2011
Early results show promise, but training and long term research are needed before wider ...
L. Chinsoo Cho, Valérie Fonteyne, Wilfried DeNeve, Simon S. Lo, Robert D. Timmerman   +4 more
openaire   +3 more sources

Stereotactic Body Radiotherapy

Seminars in Oncology, 2014
Extracranial stereotactic body radiotherapy (SBRT) has been developed and refined over the last 25 years as a means to precisely deliver ablative doses of hypofractionated radiotherapy to small targets located outside of the cranial vault. SBRT has armed the radiation oncologist with a therapeutic approach that allows for intensification of both dose ...
Laura, Kollar, Ramesh, Rengan
openaire   +2 more sources

Implementation of Stereotactic Ablative Radiotherapy (Stereotactic Body Radiotherapy)

Clinical Oncology, 2012
The National Radiotherapy Implementation Group report, Guidelines for commissioners, providers and clinicians in England 2011, on stereotactic body radiotherapy (SBRT) [1] defined SBRT as ‘the precise irradiation of an image defined extra cranial lesion associated with the use of high radiation dose delivered in a small number of fractions’. Previously,
P, Kirkbride, P J, Hoskin
openaire   +2 more sources

Stereotactic Body Radiotherapy: A Review

Clinical Oncology, 2010
Stereotactic body radiotherapy (SBRT) combines the challenge of meeting the stringent dosimetric requirements of stereotactic radiosurgery with that of accounting for the physiological movement of tumour and normal tissue. Here we present an overview of the history and development of SBRT and discuss the radiobiological rationale upon which it is based.
Martin, A., Gaya, A.
openaire   +3 more sources

Re: Stereotactic Body Radiotherapy for Oligometastatic Disease

Clinical Oncology, 2015
Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients.
G.G. Hanna, D. Landau
openaire   +5 more sources

Ultra-hypofractionated Radiotherapy (Stereotactic Body Radiotherapy)

2021
Over the past two decades, interest in hypofractionated radiotherapy for prostate cancer has intensified. Research has indicated that prostate cancer cells may have a lower alpha/beta ratio than once supposed, and hypofractionation could widen the therapeutic window.
Michael C. Repka, Edina Wang, Nima Aghdam, Siyuan Lei, Abdul Rashid, Simeng Suy, Seth Blacksburg, Sean P. Collins   +7 more
openaire   +1 more source

Stereotactic Body Radiotherapy/Stereotactic Ablative Body Radiotherapy for Lung Cancer

2013
Technological advances in radiation oncology have led to clinical implementation of novel treatment modality. Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) is an emerging treatment paradigm as a result of image-guidance technology and more sophisticated computational treatment planning system.
Hua Ren, Shanda Blackmon, Bin S. Teh
openaire   +1 more source

Stereotactic Body Radiotherapy for Liver Metastases

Seminars in Radiation Oncology, 2017
Many cancers can spread to the liver, often as the sole site of metastatic disease. For properly selected patients with limited hepatic disease and good performance status, an aggressive strategy involving radical local therapy to the site(s) of metastasis offers a chance for extended disease-free survivorship.
Karyn A, Goodman, Brian D, Kavanagh
openaire   +2 more sources

Emerging Applications of Stereotactic Body Radiotherapy

Future Oncology, 2014
Stereotactic body radiotherapy (SBRT) has been used extensively in patients with lung, liver and spinal tumors, and the treatment outcomes are very favorable. For certain conditions such as medically inoperable stage I non-small-cell lung cancer, liver and lung oligometastases, primary liver cancer and spinal metastases, SBRT is regarded as one of the ...
Simon S, Lo, Andrew, Loblaw, Eric L, Chang, Nina A, Mayr, Bin S, Teh, Zhibin, Huang, Min, Yao, Rodney J, Ellis, Tithi, Biswas, Jason W, Sohn, Mitchell, Machtay, Arjun, Sahgal   +11 more
openaire   +2 more sources

Stereotactic Body Radiotherapy for Liver Metastases

Clinical Oncology, 2015
The role for local ablative therapies in the management paradigm of oligometastatic liver disease is increasing. The evidence base supporting the use of stereotactic body radiotherapy for liver metastases has expanded rapidly over the past decade, showing high rates of local control with low associated toxicity. This review summarises the evidence base
Aitken, K, Hawkins, M
openaire   +3 more sources